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Abstract: Scopolamine hydrobromide (hyoscine) is an antimuscarinic drug which is primarily 
used in the prophylaxis and treatment of motion sickness and as a premedication to dry 
bronchial and salivary secretions. In acute overdosage, the main clinical problem is central 
nervous system (CNS) depression. In Australia, tablets containing scopolamine hydrobromide 
0.3 mg are available over the counter in packs of ten. The recommended dose for adults is one 
to two tablets as a single dose, repeated four to six hours later, if required. The maximum dose 
stated on the pack is four tablets over a 24-hour period with a caution regarding drowsiness 
and blurred vision. We describe a patient who presented with symptoms of anticholinergic 
syndrome secondary to an unintentional overdose of scopolamine. Whilst at work, the patient 
noticed that he had forgotten his prescribed medication, domperidone, at home; a friend gave 
him some travel sickness medication which contained scopolamine for relief of nausea. On a 
previous occasion, he had experienced a similar, less severe reaction with another anticholinergic 
agent, loperamide. This report highlights the need to consider nonprescription products, ie, over 
the counter medications, herbal/nutritional supplements as causes of anticholinergic syndrome 
when a patient presents with symptoms suggestive of this diagnosis.
Keywords: domperidone, scopolamine, nonprescription drugs, toxicity, anticholinergic 
syndrome
Anticholinergic syndrome is a well described toxidrome produced by the inhibition of 
cholinergic neurotransmission at muscarinic receptor sites. This may involve peripheral 
receptors (eg, in the heart, salivary glands, sweat glands, gastrointestinal tract, and 
genitourinary tract) with resulting tachycardia, hyperthermia, dry skin and mucous 
membranes, mydriasis, decreased bowel sounds and urinary retention.1 Central nervous 
system (CNS) receptors may also be affected with resulting hallucinations, psychoses, 
seizures, and coma, which generally occurs late in the course of the syndrome. The 
central anticholinergic syndrome occurs frequently, but is often unrecognized because 
many patients’ symptoms do not appear in a well defined pattern. The response to 
medications varies among patients, and there is temporal fluctuation in the course of 
an anticholinergic syndrome.2 The syndrome has been reported following the ingestion 
of a wide variety of prescription and over-the-counter medications.1,3
Scopolamine hydrobromide (also known as hyoscine hydrobromide) is an antimus-
carinic drug which has been used for the treatment of motion sickness in a transdermal 
application, as an anesthetic premedication inducing sedation and reduction of secre-
tions in the oropharynx and the bronchi.4 It is the single most effective agent to prevent Therapeutics and Clinical Risk Management 2009:5 720
Corallo et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
motion sickness.5 Doses vary according to the indication 
with a maximum oral daily dose of 1.2 mg.4 Being a tertiary 
amine, scopolamine hydrobromide is easily absorbed after 
oral intake and penetrates the blood-brain barrier by passive 
diffusion. It is important to note that scopolamine hydrobro-
mide and scopolamine butylbromide are different in many 
aspects. Both are available as nonprescription products in 
Australia. Scopolamine butylbromide is a quaternary amine 
compound that is poorly absorbed (2%–10% of an oral dose) 
and cannot readily penetrate the blood–brain barrier, there-
fore CNS effects are rare. The maximum daily oral dose is 
80 mg per day.4
The pharmacokinetic parameters of scopolamine hydro-
bromide are dependent on the dose form.6 It has limited 
bioavailability when orally administered with an absolute 
bioavailability reported to range between 3% and 27%; 
a first pass metabolism is believed to occur. Maximum 
plasma levels have occurred 23.5 ± 8.2 minutes following 
oral administration. After ocular administration, scopol-
amine hydrobromide is rapidly, efficiently and systemically 
absorbed. Following transdermal application in one study, 
delivery of scopolamine resulted in a pattern of systemic 
availability which was comparable with an intravenous 
infusion, which suggests a high bioavailability. Although 
scopolamine has been used in clinical practice for many 
years, data concerning its metabolism and renal excretion 
are limited. It appears that glucuronide conjugation is the 
relevant pathway.6 There is no data suggesting involvement 
of the hepatic cytochrome system.
Scopolamine administered in pharmacologically 
effective doses, unlike atropine and other antimuscarinic 
agents, produces CNS depressive effects such as drowsiness, 
amnesia, fatigue and dreamless sleep.6,7 High doses can 
lead to CNS stimulation (eg, excitement, restlessness, 
irritability, hallucinations, and delirium) which is similar 
to the effect observed with toxic doses of other muscarinic 
agents. In fact, symptoms observed in patients following 
scopolamine intoxication suggest a dose-dependent CNS 
effect.8 However, potentially alarming, idiosyncratic reac-
tions may occur with therapeutic doses of scopolamine 
hydrobromide.9,10 The most serious idiosyncratic reaction is 
acute psychosis with this described as confusion, agitation, 
rambling speech, hallucinations, paranoid behavior, and 
delusions. Other manifestations may include somnolence, 
dilated pupils, accelerated pulse rate, and dryness of the 
mouth with a husky quality of the voice.10 Any or all of 
these signs may occur with overdose or as adverse reactions 
involving anticholinergic drugs.11
Scopolamine hydrobromide differs strikingly from 
atropine in that it does not stimulate the medullary centers 
and therefore does not increase respiration or elevate blood 
pressure. It frequently appears to act as a cerebral depres-
sant and tends to promote sleep. A striking effect of large 
doses of scopolamine hydrobromide is the loss of memory 
for events that happened while the patient was under the 
influence of the drug.9
The range of toxicity for scopolamine hydrobromide is 
variable and unpredictable.11 Symptoms and signs of anti-
cholinergic poisoning may occur following oral ingestion 
or ocular instillation of as little as 4–5 drops of eye drops 
containing 0.25% of scopolamine hydrobromide.11,12 It is 
important to note that pharmacokinetic–pharmacodynamic 
studies of the therapeutic use of scopolamine hydrobromide 
have shown a delay between the maximal scopolamine 
concentration and the maximal presentation of neurologi-
cal effects.4
An oral dose of 50 mg atropine sulfate in humans has been 
reported to be fatal, but exact data on lethal doses of scopol-
amine are lacking. Ingestion of 10 mg has been reported to 
be lethal in children, whereas adults have survived more than 
100 mg.8,13 A dose of 0.45 mg of scopolamine (five drops of 
a 0.25% scopolamine ophthalmic solution) has caused toxic 
psychosis which lasted 10 days.14 However, it is not clear if 
this involved oral or ocular administration. In addition, the 
source of this statement cannot be verified.15
In a study involving 115 patients following acute poi-
soning from over the counter sleep preparations contain-
ing scopolamine in combination with an antihistamine 
lowest ingested dose producing life-threatening symptoms 
(eg, convulsions, arrhythmias, hallucinations) was 2–4 mg.3 
This data has been subsequently inappropriately quoted by 
other authors as a lethal dose for scopolamine.16 Lauwers 
and colleagues describe eight patients who were admitted 
to hospital after drinking tea or coffee adulterated with 
scopolamine, as confirmed by toxicological examinations.8 
First signs of toxicity included a feeling of weakness and 
lassitude in the lower limbs, quickly followed by visual 
disturbances, blurred vision and dry mouth. Subsequently 
the patients became confused, agitated, and developed 
hallucinations. All exhibited cycloplegia, extreme mydriasis, 
and had warm and dry skin. In general there was moderate 
tachycardia with normal blood pressure and respiratory 
pattern. All had normal body temperature and none had 
signs of CNS depression. All showed amnesia as from the 
appearance of the hallucinations until return of normal 
consciousness.Therapeutics and Clinical Risk Management 2009:5 721
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There is also a case report of a ten-and-a-half-year-old 
boy with acute onset of confusion and visual hallucinations 
subsequently confirmed to be due to scopolamine toxicity 
following ingestion of travel sickness medication.17 The 
amount of scopolamine hydrobromide ingested was 2.4 mg. 
Van Sassenbrocck and colleagues describe three patients 
who received 10 mg of scopolamine hydrobromide as an 
accidental overdose due to compounding errors instead 
of scopolamine butylbromide.4 In some cases, symptoms 
persisted for months and in one case the patient had been 
mistakenly diagnosed as suffering a stroke.
Widespread scopolamine toxicity occurred in Australia 
due to a manufacturing error resulting in an over-the-counter 
travel sickness preparation.18 Symptoms described in the 
reports were a combination of hallucinations, confusion, 
ataxia, and blurred vision.
The anticholinergic syndrome is a well documented 
side effect of transdermal scopolamine.19–21 There is a case 
report describing an intensive care unit (ICU) patient who 
experienced neurological deterioration and bilateral mydriasis 
six hours after application of a patch containing 1 mg of 
scopolamine to reduce bronchial secretions.22 Symptoms 
resolved after removal of the patch. Kranke and colleagues 
performed a systematic review of randomized controlled 
trials published between 1984 and 1996 to evaluate the 
efficacy and safety of transdermal scopolamine when used for 
the prevention of postoperative nausea and vomiting. Based 
on data from 23 such trials, the authors estimate the incidence 
of side-effects to be as follows: visual disturbances, 18%; dry 
mouth, 8%; dizziness, 2%; and agitation, 1%.23
Domperidone is a dopamine antagonist that is commonly 
used as an antiemetic and in the treatment of gastroparesis. 
Although structurally related to metoclopromide, it does not 
cross the blood–brain barrier and has not been reported to 
cause significant CNS side effects.24 Despite its low degree 
of CNS activity, domperidone is an effective antiemetic. 
This efficacy reflects its activity at the chemoreceptor 
trigger zone which is located in the fourth ventricle of the 
brain but outside the blood–brain barrier. Domperidone is 
distinguished from other prokinetic agents in that it has no 
cholinergic activity and its action is not inhibited by atropine. 
With oral domperidone, side effects occur in fewer than 7% 
of patients and include headaches, dry mouth, diarrhea, 
anxiety, and prolactin-related findings, eg, breast tenderness 
and enlargement, galactorrhea (uncommon), and menstrual 
irregularities. The maximum daily dose of domperidone rec-
ommended by the manufacturer is 80 mg, however doses as 
high as 120 mg a day may be required in some patients.
The main metabolic pathway of domperidone is through 
CYP3A4. In vitro and human data show that concomitant 
use of drugs that significantly inhibit this enzyme (eg, azole 
antifungals, macrolide antibiotics, amiodarone) may result in 
increased plasma levels of domperidone; high concentrations 
domperidone may prolong the QT interval.25
Case presentation
A 42-year-old truck driver presented to the emergency depart-
ment (ED) disoriented and agitated. He was accompanied by 
his wife. Because of his altered state of consciousness, he was 
unable to provide a medical history. According to his wife, 
the patient had a history of gastoparesis of unknown origin 
for which he had been prescribed domperidone 20 mg four 
times a day. His past history was unremarkable except for 
a hernia repair. There was no history of alcohol abuse and 
he was not taking any other medications. He had omitted 
to take his usual lunchtime dose of domperidone because 
he had left his tablets at home. When he arrived home, he 
ingested 60–80 mg domperidone as a single dose because 
of increasing nausea. Three hours later, the patient started 
to ramble and to behave inappropriately, becoming agitated 
and confused.
On presentation to the ED, the patient was noted to be 
disorientated and appeared to be responding to visual and 
auditory hallucinations; he was trying to touch imaginary 
objects. The Glasgow Coma Score (GCS) was 13/15. 
Presenting vital signs were pulse rate 100 beats/min, respi-
ratory rate 20/min, temperature 37.8°C, and blood pressure 
123/74 mmHg. Abnormal findings on physical examination 
were warm, dry skin, dilated pupils, and repeated myoclonic 
jerking of the jaw and limbs. Initial diagnosis included intra-
cranial hemorrhage and metabolic causes. Investigations 
performed revealed electrolyte levels, thyroid function tests, 
glucose levels, and renal function all within normal limits. 
Blood alcohol, salicylate, and acetaminophen levels were 
not detectable. An electrocardiogram showed sinus rhythm. 
A computed tomography of the brain was normal.
A toxicology opinion was sought and symptoms were 
considered to be consistent with a central anticholinergic 
syndrome. Two doses of midazolam 5 mg, intramuscularly 
were given 10 minutes apart for the management of increas-
ing agitation and the myoclonic jerking. Postsedation, the 
patient’s conscious state deteriorated rapidly (GCS 3/15) and 
he required intubation for airway protection. He was admitted 
to the ICU. An indwelling urinary catheter was inserted. 
In the ICU, sedation was initially maintained with propofol 
5–10 ml/hour for tube tolerance. The patient was afebrile, Therapeutics and Clinical Risk Management 2009:5 722
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hemodynamically stable, co-operative and pleasant, with 
good urine output. He improved rapidly and was extubated 
three hours after arriving in ICU.
After the patient was extubated, there was some recall 
returning from the previous day’s events. Upon repeated 
questioning, it was revealed that approximately 5–6 hours 
prior to onset of symptoms he had taken four tablets of 
scopolamine hydrobromide as a single dose (1.2 mg) which 
belonged to a friend. He had not taken this preparation previ-
ously and denied taking any other medications. A diagnosis 
of anticholinergic toxicity secondary to scopolamine hydro-
bromide was made based on this information and his clinical 
picture. The patient was discharged later on the same day 
with slightly blurred vision. He was advised not to exceed 
the recommended dose of his medications and was also 
provided with a list of drugs with anticholinergic properties 
and advised to avoid these unless instructed otherwise by 
his doctor.
A review of the medical history revealed that the patient 
had presented 12 months earlier with similar, less severe 
symptoms consisting of slurred speech, difficulty in swal-
lowing following ingestion of another anticholinergic agent, 
loperamide capsules for diarrhea. He had taken one capsule 
after each loose bowel action up to 12 capsules over 24 hours 
(recommended maximum is eight capsules over 24 hours).
Discussions
The symptoms observed in our patient are consistent with 
the anticholinergic syndrome, with peripheral and central 
manifestations, including myoclonic jerking, a symptom 
not often described in published case reports of scopolamine 
intoxication. Because of the information initially provided by 
the patient’s family, symptoms were attributed to ingestion 
of an excessive dose of domperidone. However, a literature 
search did not retrieve any reports of an anticholinergic 
syndrome associated with this drug nor of interactions with 
scopolamine.24,25 This was confirmed by the manufacturer. 
In addition, the amount of domperidone ingested (40–60 mg) 
was not considered to be a significant overdose.24 It was 
subsequently established that the patient had ingested an 
unintentional overdose of scopolamine hydrobromide.
The recommended dose for adults is one to two tablets 
of 0.3 mg as a single dose, repeated four to six hours later, 
if required, with a maximum dose of four tablets (1.2 mg) over 
a 24-hour period.26 Our patient had taken 1.2 mg as a single 
dose and symptoms appeared five hours later. This is consis-
tent with an overdose of scopolamine, when manifestation 
of neurological symptoms is delayed. A similar, less severe 
reaction occurred on a previous occasion following ingestion 
of another anticholinergic agent, loperamide. Application of 
the Naranjo probability scale to our case report assigns the 
likelihood that the symptoms of anticholinergic toxicity were 
caused by scopolamine hydrobromide as “probable”.27
The anticholinergic syndrome is well documented 
following therapeutic doses of transdermal scopolamine 
and following ocular instillation. This is compatible with the 
pharmacokinetics of the drug. Our case describes a central 
anticholinergic syndrome following 1.2 mg of scopolamine 
hydrobromide, which is significantly lower than doses 
described in any published case report. Most of the published 
reports either do not specify the amounts involved or describe 
ingestion of scopolamine with other agents. When an amount 
is specified, doses of scopolamine hydrobromide 2.1 to 10 mg 
produced symptoms of anticholinergic toxicity but this did 
not include seizure activity .4,17,28
Our case suggests an increased susceptibility to anti-
cholinegic effects of drugs. On two occasions the patient 
had exceeded the recommended dose by not adhering to the 
manufacturer’s instructions. Most cases of anticholinergic 
intoxication can be treated by discontinuing the offend-
ing agent.16 However, for more serious cases it may be 
necessary to hospitalize the patient for close monitoring 
and observation. Benzodiazepines can be used to manage 
agitation and in our case, seizure activity. Supportive care 
is also necessary to cool the patient and maintain hydration. 
Patients who experience confusion and hallucinations should 
be monitored closely since they may be a danger both to 
themselves and others.16
A search of the database of the Australian Therapeutic 
Goods Administration’s Adverse Drug Reaction Advisory 
Committee (ADRAC) from March 1986 to April 2009 
revealed 14 reports of adverse reactions to one brand of 
scopolamine hydrobromide tablets, Kwells (Bayer Consumer 
Care, Pymble, NSW, Australia) and of these eight described 
symptoms of anticholinergic toxicity. During the same 
period there were 225 reports of anticholinergic syndrome 
associated with another nonprescription preparation 
containing scopolamine hydrobromide, Travacalm HO 
(Key Pharmaceuticals Pty. Ltd., Macquarie Park, NSW, 
Australia). Nearly all these reports, describing combinations 
of hallucinations, confusion, ataxia and blurred vision, were 
submitted to ADRAC in 2003. Travacalm was recalled and 
laboratory testing revealed that the scopolamine content of 
the tablets ranged from none to seven times the dose stated 
on the label.28 This highlights the importance of reporting 
adverse drug reactions to the relevant agencies.Therapeutics and Clinical Risk Management 2009:5
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The unusual etiology makes this case a paradigmatic example 
of how a detailed medical history can help to achieve a cor-
rect diagnosis and in rationalizing any further investigations. 
It highlights the need to consider nonprescription products, 
ie, over-the-counter medications, herbal/nutritional supple-
ments as causes of anticholinergic syndrome when a patient 
presents with symptoms suggestive of this diagnosis.13 This 
case illustrates that ingestion of scopolamine hydrobromide 
in doses which are marginally above the recommended 
range may produce symptoms of anticholinergic toxicity. 
In addition, some patients may be particularly susceptible 
to the anticholinergic effects of this drug and should be 
counseled accordingly. This case illustrates that the range 
of toxicity with respect to oral scopolamine is variable and 
unpredictable. Clinical judgment is more important than 
attempting to determine the amount ingested.
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